Open Actively Recruiting

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

About

Brief Summary

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term.

Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia.

Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team.

The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 3

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
51 Years

Inclusion criteria:

* Have a study partner who interacts with the patient on a regular basis. Further inclusion criteria apply.

Exclusion criteria:

Further exclusion criteria apply.

Join this Trial

Share:
Study Stats
Protocol No.
23-5213
Category
Mental Health
Principal Investigator
Keith Nuechterlein
Contact
Fe Asuan
Location
  • UCLA Westwood
For Providers
NCT No.
NCT05211947
For detailed technical eligibility, visit ClinicalTrials.gov.